Paving the way for Merck's buyout, Seagen loses arbitration dispute with Daiichi Sankyo over ADC tech
As Seagen awaits a final buyout offer from Merck that could be in the territory of $40 billion, Seagen revealed Friday afternoon that it lost an arbitration dispute with Daiichi Sankyo relating to the companies’ 2008 collaboration around the use of antibody-drug conjugate (ADC) technology.
But that loss likely won’t matter much when it comes to Merck’s deal.
After breaking off its pact with Daiichi in mid-2015, the two companies battled over “linker” tech — a chemical bridge between an ADC’s antibody component and the cytotoxic payload — that Seagen claims Daiichi would improve upon and implement in its current generation of ADCs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.